{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:02:28Z","timestamp":1781244148082,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jtho.2016.01.014","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T04:17:42Z","timestamp":1454386662000},"page":"758-768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes"],"prefix":"10.1016","volume":"11","author":[{"given":"Wieneke A.","family":"Buikhuisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Scharpfenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan W.","family":"Griffioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina M.","family":"Korse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"van Tinteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.01.014_bib1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib2","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.01.014_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0031-6997(24)01448-0","article-title":"Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation","volume":"52","author":"Griffioen","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jtho.2016.01.014_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2016.01.014_bib6","first-page":"2063","article-title":"Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma","volume":"18","author":"Linder","year":"1998","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtho.2016.01.014_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.01.014_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D","article-title":"Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma","volume":"182","author":"Kumar-Singh","year":"1997","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jtho.2016.01.014_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib10","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1002\/cncr.28766","article-title":"Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic\/pharmacodynamic and quality-of-life assessments","volume":"120","author":"Locati","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2016.01.014_bib11","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nm.2018","article-title":"Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth","volume":"15","author":"Albuquerque","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2016.01.014_bib12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/ATVBAHA.110.213124","article-title":"A\u00a0disintegrin and metalloprotease 10 is a novel mediator of vascular endothelial growth factor-induced endothelial cell function in angiogenesis and is associated with atherosclerosis","volume":"30","author":"Donners","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtho.2016.01.014_bib13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/CIRCRESAHA.108.184416","article-title":"VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling","volume":"103","author":"Swendeman","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.jtho.2016.01.014_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1183\/09031936.00074009","article-title":"Current data on predictive markers for anti-angiogenic therapy in thoracic tumours","volume":"36","author":"Reinmuth","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2016.01.014_bib15","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","article-title":"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy","volume":"104","author":"Ebos","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2016.01.014_bib16","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","article-title":"Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer","volume":"29","author":"Rugo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/bjc.2012.406","article-title":"Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours","volume":"107","author":"Kozloff","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.01.014_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.critrevonc.2012.12.006","article-title":"Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials","volume":"87","author":"Sonpavde","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtho.2016.01.014_bib19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/157016110790226660","article-title":"Thromboembolic events in patients treated with anti-angiogenic drugs","volume":"8","author":"Ferroni","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jtho.2016.01.014_bib20","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","article-title":"Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors","volume":"17","author":"Rini","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.01.014_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"Kindler","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/1471-2407-14-290","article-title":"Randomized phase II study of pemetrexed\/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer","volume":"14","author":"Belani","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2016.01.014_bib23","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A\u00a0phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.01.014_bib26","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A\u00a0phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib27","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib28","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.01.014_bib29","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2016.01.014_bib30","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/jco.2015.33.15_suppl.7500","article-title":"Bevacizumab 15mg\/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in malignant pleural mesothelioma (MPM): results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial","volume":"33","author":"Zalcman","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416003518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416003518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T08:33:23Z","timestamp":1748766803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416003518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1556086416003518"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.01.014","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}